Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival

Genmab announced Phase 3 EPCORE DLBCL-4 topline results: fixed-duration epcoritamab + lenalidomide met its primary endpoint, cutting the risk of progression or death by 60% (HR 0.40, 95% CI 0.30–0.55; p<0.0001) and 56% (HR 0.44, 95% CI 0.33–0.60; p<0.0001) vs R-GemOx based on different censoring rules. The company said the regimen’s safety profile is consistent with prior epcoritamab and lenalidomide results. Data will be submitted to regulatory authorities and for presentation at a future medical meeting.

Analysis

This is more important as a valuation de-risking event for GMAB than as a near-term revenue bridge. The real mechanism is that a fixed-duration, subcutaneous, chemo-free regimen lowers the operational friction that has historically kept relapse/refractory lymphoma therapy concentrated in specialty centers; that should improve adoption odds in the CAR-T-ineligible population and gradually pull share from infusion-heavy options. The market may still underappreciate how often convenience, not just efficacy, determines second-line oncology penetration.

ABBV participates, but the economics are more incremental than transformative: this adds another proof point that the oncology collaboration can produce durable assets, yet it does not meaningfully alter AbbVie’s consolidated earnings trajectory by itself. The bigger second-order winners are the off-the-shelf bispecific ecosystem and community oncology channels; the biggest losers are center-intensive competitors, especially CAR-T franchises and any regimen that relies on multi-agent chemotherapy plus supportive care logistics. Roche and other lymphoma incumbents face the clearest share-risk if prescribers view this as the easier default option.

The key risk is that topline PFS alone can overstate commercial impact. Over the next 1-3 months, the market will focus on the abstract, safety granularity, and regulator feedback; over 6-18 months, the issue is whether this becomes a sequencing standard or just another niche salvage option. Consensus may be underweighting the convenience premium, but overstating the earnings contribution before label scope and uptake are proven.

Key Decisions for Investors

• Long GMAB on weakness over the next 1-2 sessions; use any post-headline pullback to build exposure for a 3-6 month regulatory catalyst path. Risk/reward favors GMAB because the stock has higher operating leverage to pipeline de-risking than ABBV.
• Buy GMAB 6-12 month call spreads to express label-expansion optionality while limiting downside if the market decides the data are already in the price. Falsifier: weak follow-up detail on depth/duration of benefit or unexpected safety signal at the full presentation.
• Pair long GMAB / short RHHBY as a relative-value trade on bispecific share capture in DLBCL over the next 3-12 months. This works best if community-oncology adoption data or regulator commentary suggests easier outpatient uptake than older lymphoma regimens.
• For ABBV holders, use strength to hedge rather than add aggressively; this is positive for the oncology narrative but unlikely to move the consolidated multiple on its own. Falsifier: no meaningful commentary on near-term commercial milestones or label breadth in the next update.
• Set an alert for the medical-meeting abstract and regulatory filing cadence; if management cannot translate the topline into a clear submission timeline, reduce conviction. The trade thesis weakens materially if approval timing slips beyond 1H27 or if prescriber uptake looks constrained by competitive bispecifics.